Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 881

Sort by

Sort Order Select

Journal Articles

OBF1 and Oct factors control the germinal center transcriptional program

Shuang Song, Chun Cao, Mohamed-Amin Choukrallah, Fengyuan Tang, Gerhard Christofori, Hubertus Kohler, Fabian Wu, Barna D. Fodor, Mathias Frederiksen, Simon N. Willis, Jacob T. Jackson, Stephen L. Nutt, Stefan Dirnhofer, Michael B. Stadler, Patrick Matthias

Blood (2021) 137 (21): 2920–2934.

https://doi.org/10.1182/blood.2020010175

Published: 2021

Includes: Supplemental data

Journal Articles

Emerging therapies for inv(16) AML

Sridevi Surapally, Daniel G. Tenen, John A. Pulikkan

Blood (2021) 137 (19): 2579–2584.

https://doi.org/10.1182/blood.2020009933

Published: 2021

Journal Articles

Cancer genes and blood clots

Janusz Rak

Blood (2021) 137 (15): 1996–1997.

https://doi.org/10.1182/blood.2020009967

Published: 2021

Journal Articles

Dynamic CTCF binding directly mediates interactions among cis -regulatory elements essential for hematopoiesis

Qian Qi, Li Cheng, Xing Tang, Yanghua He, Yichao Li, Tiffany Yee, Dewan Shrestha, Ruopeng Feng, Peng Xu, Xin Zhou, Shondra Pruett-Miller, Ross C. Hardison, Mitchell J. Weiss, Yong Cheng

Blood (2021) 137 (10): 1327–1339.

https://doi.org/10.1182/blood.2020005780

Published: 2021

Includes: Supplemental data

Journal Articles

A common protein target for an uncommon subtype of AML

Martin Carroll

Blood (2020) 136 (4): 377–378.

https://doi.org/10.1182/blood.2020006487

Published: 2020

Journal Articles

CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia

Blood (2020) 136 (4): 387–400.

https://doi.org/10.1182/blood.2019003267

Published: 2020

Includes: Supplemental data

Journal Articles

Ldb1 is required for Lmo2 oncogene–induced thymocyte self-renewal and T-cell acute lymphoblastic leukemia

LiQi Li, Apratim Mitra, Kairong Cui, Bin Zhao, Seeyoung Choi, Jan Y. Lee, Daniel B. Stamos, Dalal El-Khoury, Claude Warzecha, Karl Pfeifer, Joyce Hardwick, Keji Zhao, Bryan Venters, Utpal P. Davé, Paul E. Love

Blood (2020) 135 (25): 2252–2265.

https://doi.org/10.1182/blood.2019000794

Published: 2020

Includes: Supplemental data

Journal Articles

Tearing ATL apart to find HTLV’s sinister plans

Mark Y. Chiang

Blood (2020) 135 (12): 887–889.

https://doi.org/10.1182/blood.2020004998

Published: 2020

Journal Articles

HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms

Blood (2020) 135 (3): 191–207.

https://doi.org/10.1182/blood.2019895326

Published: 2020

Includes: Supplemental data

Journal Articles

Cohesin-dependent regulation of gene expression during differentiation is lost in cohesin-mutated myeloid malignancies

Daniel Sasca, Haiyang Yun, George Giotopoulos, Jakub Szybinski, Theo Evan, Nicola K. Wilson, Moritz Gerstung, Paolo Gallipoli, Anthony R. Green, Robert Hills, Nigel Russell, Cameron S. Osborne, Elli Papaemmanuil, Berthold Göttgens, Peter Campbell, Brian J. P. Huntly

Blood (2019) 134 (24): 2195–2208.

https://doi.org/10.1182/blood.2019001553

Published: 2019

Includes: Supplemental data

Journal Articles

Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors

Christopher Peter Mill, PhD BA, Warren Fiskus, BSc,PhD, Dyana T. Saenz, PhD, Bernardo H Lara, Vrajesh Karkhanis, PhD, Taghi Manshouri, PhD, Isean Bhalla, Nancy Shao, James V Maher, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2019) 134 (Supplement_1): 538.

https://doi.org/10.1182/blood-2019-125142

Published: 2019

Journal Articles

Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL)

Blood (2019) 134 (Supplement_1): 516.

https://doi.org/10.1182/blood-2019-129520

Published: 2019

Journal Articles

Myeloid-Lineage Enhancers Drive Oncogene Synergy and Represent a Novel Therapeutic Target in CSF3R-CEBPA Mutant AML

Theodore Braun, MD PhD, Cody Coblentz, Sarah A Carratt, PhD BS, Mariam Okhovat, PhD, Amy Foley, MEng., Zachary Schonrock, BS, Kimberly Nevonen, Rhonda E. Ries, MA, Shannon K. McWeeney, PhD, Claus Nerlov, PhD, Soheil Meshinchi, MD PhD, Lucia Carbone, PhD, Brian J. Druker, Julia E. Maxson, PhD

Blood (2019) 134 (Supplement_1): 543.

https://doi.org/10.1182/blood-2019-124773

Published: 2019

Journal Articles

CRISPR-Cas9 Genome Editing of γ-Globin Promoters in Human Hematopoietic Stem Cells to Induce Erythrocyte Fetal Hemoglobin for Treatment of β-Hemoglobinopathies

Blood (2019) 134 (Supplement_1): 2066.

https://doi.org/10.1182/blood-2019-131318

Published: 2019

Journal Articles

Proteomic Profiling and Mechanistic Investigating of a Novel Anti-Cancer Small Molecule Inhibitor of Sec61

Yu Qian, PhD, Henry W.B. Johnson, PhD, Christopher J. Kirk, PhD, Eric Lowe, BS, Dustin McMinn, PhD, Beatriz Millare, BS, Tony Muchamuel, MS, Jinhai Wang, PhD

Blood (2019) 134 (Supplement_1): 2076.

https://doi.org/10.1182/blood-2019-125988

Published: 2019

Journal Articles

Design and Characterization of FLT210, a Potent Next Generation AAV-hFVIII Vector Candidate

Blood (2019) 134 (Supplement_1): 4638.

https://doi.org/10.1182/blood-2019-128490

Published: 2019

Journal Articles

Clinical ALK5 Inhibitor, Vactosertib, Reverses TGFβ-1 Stimulated Smad-2 Driven Ineffective Hematopoiesis in MDS

Srinivas Aluri, Kimo Bachiashvili, MD, Anjali Budhathoki, MD, Tushar D Bhagat, PhD, Gaurav S Choudhary, PhD, Shanisha Gordon, Nandini Ramachandra, Kith Pradhan, PhD, Shahina Maqbool, Aditi Shastri, MD, Jung Im Huh, Sunjin Hwang, Kim Seong-Jin, PhD, Hui Zhang, Britta Will, PhD, Amittha Wickrema, PhD, Ulrich G. Steidl, MD PhD, Amit Verma, MBBS

Blood (2019) 134 (Supplement_1): 2990.

https://doi.org/10.1182/blood-2019-127561

Published: 2019

Journal Articles

Genetic Interactions between Cohesin Mutations and Core-Binding Factor Driver Oncogenes

Katelyn E Heimbruch, Sridhar Rao, MD PhD

Blood (2019) 134 (Supplement_1): 2540.

https://doi.org/10.1182/blood-2019-125893

Published: 2019

Journal Articles

Targeted Inhibition of the NUP98-NSD1 Fusion Oncogene in AML

Sagarajit Mohanty, MSc, Nidhi Jyotsana, PhD, Amit Sharma, PhD, Basem Othman, Arnold Kloos, PhD, Madhvi Mandhania, MSc, Renate Schottmann, Euan Ramsay, PhD, Hans- Peter Vornlocher, PhD, Arnold Ganser, MD, Felicitas Thol, MD, Michael Heuser, MD

Blood (2019) 134 (Supplement_1): 2545.

https://doi.org/10.1182/blood-2019-123709

Published: 2019

Journal Articles

Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis

Jaewoong Lee, PhD, Gang Xiao, PhD, Kadriye Nehir Nehir Cosgun, PhD, Huimin Geng, PhD, Ning Ma, PhD, Lai N Chan, PhD, Kohei Kume, PhD, Matthew Nix, PhD, Zhengshan Chen, MD PhD, Chun-Wei David Chen, PhD, Jianjun Chen, PhD, Vishal Khairnar, PhD, Arun P. Wiita, MD PhD, Andrei Thomas-Tikhonenko, PhD, Michael Farzan, MD PhD, Michael S. Diamond, PhD, Jae U Jung, PhD, Nagarajan Vaidehi, PhD, Markus Müschen, MD PhD

Blood (2019) 134 (Supplement_1): 2782.

https://doi.org/10.1182/blood-2019-127615

Published: 2019

NARROW

OBF1 and Oct factors control the germinal center transcriptional program

Emerging therapies for inv(16) AML

Cancer genes and blood clots

Dynamic CTCF binding directly mediates interactions among cis -regulatory elements essential for hematopoiesis

A common protein target for an uncommon subtype of AML

CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia

Ldb1 is required for Lmo2 oncogene–induced thymocyte self-renewal and T-cell acute lymphoblastic leukemia

Tearing ATL apart to find HTLV’s sinister plans

HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms

Cohesin-dependent regulation of gene expression during differentiation is lost in cohesin-mutated myeloid malignancies

Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors

Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL)

Myeloid-Lineage Enhancers Drive Oncogene Synergy and Represent a Novel Therapeutic Target in CSF3R-CEBPA Mutant AML

CRISPR-Cas9 Genome Editing of γ-Globin Promoters in Human Hematopoietic Stem Cells to Induce Erythrocyte Fetal Hemoglobin for Treatment of β-Hemoglobinopathies

Proteomic Profiling and Mechanistic Investigating of a Novel Anti-Cancer Small Molecule Inhibitor of Sec61

Design and Characterization of FLT210, a Potent Next Generation AAV-hFVIII Vector Candidate

Clinical ALK5 Inhibitor, Vactosertib, Reverses TGFβ-1 Stimulated Smad-2 Driven Ineffective Hematopoiesis in MDS

Genetic Interactions between Cohesin Mutations and Core-Binding Factor Driver Oncogenes

Targeted Inhibition of the NUP98-NSD1 Fusion Oncogene in AML

Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only